Hirose C, Iihara H, Funaguchi N, Endo J, Ito F, Yanase K, Kaito D, Sasaki Y, Gomyo T, Sakai C, Ohno Y, Suzuki A
Pharmazie. 2019 Oct 1;74(10):620-624. doi: 10.1691/ph.2019.9497.
Rikkunshito has been shown to improve upper gastrointestinal symptoms and anorexia. The aim of this study was to evaluate whether rikkunshito improves chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin (CBDCA)-based chemotherapy. A retrospective before-and-after comparison study was conducted in patients with thoracic cancer receiving the first cycle of CBDCA-based chemotherapy. Among 61 eligible patients, 34 received standard antiemetic therapy with a combination of 5-hydroxytryptamine-3 receptor antagonist and dexamethasone from September 2012 and June 2013 (standard group), while the other 27 received the standard antiemetic therapy plus oral rikkunshito from July 2013 and December 2014 (rikkunshito group). The rates of no nausea showed no significant difference between the standard and rikkunshito group (Overall phase: 64.7 % for standard group 74.1 % for rikkunshito group, = 0.579). Subgroup analysis indicated that, in female patients, the rates of no nausea in rikkunshito groups was significantly higher than in standard group (overall phase: 44.4 % 100 %, = 0.034). Rikkunshito did not demonstrate an additional prophylactic effect on standard antiemetic therapy for nausea in patients with thoracic cancer receiving CBDCA-based chemotherapy, but showed a prophylactic effect of nausea in female patients.
已证实理气和中汤可改善上消化道症状及食欲不振。本研究旨在评估理气和中汤对接受以卡铂（CBDCA）为基础化疗的胸段癌患者化疗所致恶心的改善情况。对接受首个周期以CBDCA为基础化疗的胸段癌患者进行回顾性前后对照研究。在61例符合条件的患者中，34例在2012年9月至2013年6月期间接受了5-羟色胺-3受体拮抗剂与地塞米松联合的标准止吐治疗（标准组），而另外27例在2013年7月至2014年12月期间接受了标准止吐治疗加口服理气和中汤（理气和中汤组）。无恶心发生率在标准组和理气和中汤组之间无显著差异（总体阶段：标准组为64.7%，理气和中汤组为74.1%，P = 0.579）。亚组分析表明，在女性患者中，理气和中汤组的无恶心发生率显著高于标准组（总体阶段：44.4%对100%，P = 0.034）。理气和中汤对接受以CBDCA为基础化疗的胸段癌患者的标准止吐治疗未显示出额外的预防恶心作用，但对女性患者显示出预防恶心的作用。
